Menofem
Natural health product licensed in Canada
- Licence holder
- Xymogen
- NPN or DIN-HM
- 80070151
- Status
- Inactive licence
- Licence date
- 9 June 2016
- Revision date
- 1 September 2016
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Dioscorea villosa L.: Les matières premières végétales doivent avoir subi les étapes traditionnelles d'épluchage, de lavage et de traitement thermique. L'absence d'alcaloïdes et de composés cyanogènes doit être démontrée par des bulletins d'analyse.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Actaea racemosa L.: Seuls les extraits aqueux et hydro-alcooliques de titre faible (30 %) sont admis. La portion journalière recommandée ne doit pas conduire à une ingestion de glycosides de triterpène (calculés comme 27-déoxyactéine) supérieure à 3 mg.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Leonurus cardiaca L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les femmes enceintes
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Trifolium pratense L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Glycyrrhiza glabra L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Taraxacum officinale Source : Racine Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 266.7 mg | 66.67 mg | Not calculated |
| Dioscorea villosa Source : Racine et rhizome Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 666.7 mg | 66.67 mg | Not calculated |
| Vitex agnus-castus Source : Fruit Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 666.7 mg | 66.67 mg | Not calculated |
| Actaea racemosa Source : Racine Extract : Matériel brut sec Extraction ratio : 8:1 Dry plant equivalent : 400 mg | 50 mg | Not calculated |
| Withania somnifera Source : Racine | 33.33 mg | Not calculated |
| Leonurus cardiaca Source : Plante Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 133.33 mg | 33.33 mg | Not calculated |
| Trifolium pratense Source : Fleur | 33.33 mg | Not calculated |
| Angelica sinensis Source : Racine Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 250 mg | 25 mg | Not calculated |
| Glycyrrhiza glabra Source : Racine Potency : 26 % glycyrrhizin | 8.33 mg | Not calculated |
Non-medicinal ingredients
Cellulose microcristalline, Acide stéarique, Stéarate de magnésium, Silice, Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1 Capsule | 1 day |
Uses authorised in Canada
Used in Herbal Medicine to help relieve premenstrual symptoms, as a hormone normaliser to help stabilise menstrual cycle irregularities and to help relieve symptoms associated with menopause, such as hot flushes.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you are pregnant or breast-feeding. Do not use if you have heart disease, high blood pressure, kidney or liver disorder, diabetes or edema, hormone sensitive conditions such as uterine, endometrial, breast, or ovarian cancer as well as endometriosis and uterine fibroids or are taking other diuretic products. Do not use if you have a p[protein S deficiency as wild yam may increase the risk of thrombosis.
- Précautions et mises en garde
Consult a health care practitioner prior to use: if you have gall bladder disease, intestinal obstruction; if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy. If symptoms persist or worsen, consult a health care practitioner.
- Effets indésirables connus
Hypersensitivity/allergy has been known to occur; in such a case, discontinue use. If you experience dizziness, confusion, muscle weakness or pain, abnormal heartbeat and/or difficulty breathing discontinue use and seek medical attention immediately. Discontinue use if diarrhea, stomach irritation, and/or uterine bleeding occurs.
Source
Official Health Canada record, licence 80070151
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2016. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.